Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edesa Biotech鈥檚 SEC reports are packed with clinical data tables, R&D cost breakdowns, and milestone disclosures that can stretch past 200 pages. Finding when a vitiligo study hits Phase II or how much cash runway remains shouldn鈥檛 take an entire afternoon.
Stock Titan tackles that problem head-on. Our AI reads every newly posted Edesa Biotech quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the instant they appear on EDGAR. It then highlights what most investors hunt for: trial enrollment updates, government grant inflows, and liquidity ratios鈥攄istilled into plain English. Curious about director stock sales? Get Edesa Biotech Form 4 insider transactions real-time alerts so you never miss a trade.
Use the platform to:
- Track Edesa Biotech insider trading Form 4 transactions and spot buying trends before the market reacts.
- Compare quarter-over-quarter R&D spend with one-click Edesa Biotech earnings report filing analysis.
- Review the Edesa Biotech proxy statement executive compensation section without wading through legalese.
Whether you鈥檙e asking 鈥淗ow do I understand Edesa Biotech SEC documents with AI?鈥� or searching for 鈥淓desa Biotech executive stock transactions Form 4,鈥� this page delivers. AG真人官方-time feeds, AI-powered summaries, and expert context turn dense biotech disclosures into actionable insights you can trust.
Edesa Biotech, Inc. reported a strengthened liquidity position driven by private placements: cash and cash equivalents increased to $12.36 million at June 30, 2025 and working capital was approximately $12.1 million. For the nine months ended June 30, 2025 the company recorded a net loss of $4.96 million, contributing to an accumulated deficit of $63.65 million. The company received gross proceeds of about $15.0 million from a Series B-1 private placement and $1.54 million from a Series A-1 issuance.
The company continues clinical development across two programs: EB05 is participating in a BARDA-funded platform trial and EB06 is advancing toward a Phase 2 vitiligo study with manufacturing preparation underway. The Canadian Strategic Innovation Fund committed up to C$23 million (partially repayable) to support Phase 3 and related activities. Management states a going concern material uncertainty exists and further financing or strategic activities will be required to fund development beyond current expectations.
Edesa Biotech announced its financial results for the three- and nine-month periods ended June 30, 2025 via a press release that is attached to this Form 8-K as Exhibit 99.1. The filing expressly states the Earnings Release is furnished and shall not be deemed "filed" under the Exchange Act, so it is not subject to Section 18 liabilities and is not incorporated by reference in other filings unless specifically cited. This 8-K itself does not include financial figures or operational details.
On 08/04/2025, Edesa Biotech (EDSA) filed a Form 4 disclosing that CEO, Director and 10% owner Pardeep Nijhawan acquired 6,802 common shares on 08/01/2025. The shares were issued as restricted share units that vested immediately at a cost basis of $0 under the company鈥檚 2019 Equity Incentive Compensation Plan.
Following the grant, Nijhawan鈥檚 direct holdings rose to 463,755 shares. He also reports 459,428 shares held indirectly through affiliated entities and a family trust: 341,702 by Pardeep Nijhawan Medicine Professional Corp., 53,104 by 1968160 Ontario Inc., 32,013 by The Digestive Health Clinic Inc., and 32,609 by The New Nijhawan Family Trust 2015. No derivative securities or dispositions were reported.
The filing reflects a routine equity award that slightly increases insider ownership and further aligns the CEO鈥檚 economic interests with those of common shareholders; it does not signal any immediate strategic or financial shift.
FAQ
What is the current stock price of Edesa Biotech (EDSA)?
What is the market cap of Edesa Biotech (EDSA)?
